

HE Dr Alisher Kayumovich Shadmanov
Minister of Health
Ministry of Health
Navoi Str. 12
700011 Tashkent
The Republic of Uzbekistan

13 December 2017

Decision Letter: Request for 2018 Renewal of Gavi vaccine support

Your Excellency,

I am writing in relation to Uzbekistan's request for renewal of the New Vaccine Support (NVS) for Pneumococcal Vaccine, Rotavirus Vaccine and Inactivated Polio Vaccine support that was reviewed by Gavi Secretariat Review on 25 of October 2017.

Following the recommendations made by the Secretariat's Review, I am pleased to inform you that Gavi has **approved** Uzbekistan's request to renew Gavi vaccine support for 2018, subject to several conditions and requirements as specified in the Appendices to this letter.

The Appendices include the following important information:

- Appendix A: Financial and Programmatic information –Support for Pneumococcal Vaccine (PCV)
- Appendix B: Financial and Programmatic information –Support for Inactivated Polio Vaccine (IPV)
- Appendix C: Financial and Programmatic information –Support for Rotavirus Vaccine
- Appendix D: Financial and Programmatic information –Support for Injection Safety Devices

Please do not hesitate to contact my colleague Ms Nilgun Aydogan at naydogan@gavi.org if you have any questions or concerns.

Yours sincerely,



Hind Khatib-Othman
Managing Director, Country Programmes

cc: The Minister of Finance
The EPI Manager
WHO Country Representative
WHO EURO
UNICEF Country Representative
WHO HQ
UNICEF Programme Division
UNICEF Supply Division

Decision Letter Uzbekistan - Support for Pneumococcal Vaccine

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Uzbekistan				
2. Grant number: 1719-UZB-12c-X / 15-UZB-08c-Y				
3. Date of Decision Letter: 13/12/2017				
4. Date of the Partnership Framework Agreement: 07/02/2014				
5. Programme title: New Vaccine Support (NVS), Pneumococcal Routine				
6. Vaccine type: Pneumococcal				
7. Requested product presentation and formulation of vaccine: Pneumococcal (PCV13), 1 dose per vial , LIQUID				
8. Programme duration¹: 2015 - 2019				
9. Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement)				
	2015-2017	2018	2019	Total²
Programme Budget (US\$)	14,292,201 ³	3,643,000	2,628,000	20,563,201
10. Vaccine introduction grant (in US\$): US\$505,000 disbursed on 04 June 2015.				
11. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement) ⁴				
Type of supplies to be purchased with Gavi funds in each year		2015-2017	2018	
Number of Pneumococcal vaccines doses			895,700	
Annual Amounts (US\$)		14,292,201 ⁵	3,643,000	
12. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.				
13. Self-procurement: Not applicable.				
14. Co-financing obligations: Reference code: 1719-UZB-12c-X-C According to the co-financing policy, the Country falls within the group Accelerated transition. The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.				
Type of supplies to be purchased with Country funds in each year		2018	2019	
Number of vaccine doses		1,305,000	1,736,500	
Number of AD syringes		1,393,900		
Number of safety boxes		15,350		
Value of vaccine doses (US\$)		4,306,484		
Total co-financing payments (US\$) (including freight)		4,504,500	5,993,500	
15. Operational support for campaigns: Not applicable				

¹ This is the entire duration of the Programme.

² This is the total amount endorsed by Gavi for the entire duration of the Programme.

³ This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices.

Annual amounts for 2017 onwards include only vaccine costs and freight.

⁴ This is the amount that Gavi has approved.

⁵ This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

16. Additional reporting requirements: Not applicable	
Reports and other information	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	15 May
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat
17. Financial clarifications: Not applicable.	
18. Other conditions: Not applicable.	

Signed by,



On behalf of Gavi

Hind Khatib-Othman
Managing Director, Country Programmes
13 December 2017

Decision Letter
Uzbekistan - Support for Inactivated Polio Vaccine

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Uzbekistan			
2. Grant number: 1518-UZB-25b-X / 15-UZB-08h-Y			
3. Date of Decision Letter: 13/12/2017			
4. Date of the Partnership Framework Agreement: 07/02/2014			
5. Programme title: New Vaccine Support (NVS) – Inactivated Polio Vaccine, routine			
6. Vaccine type: Inactivated Polio Vaccine (IPV)			
7. Requested product presentation and formulation of vaccine⁶: Inactivated Polio Vaccine, 5 doses per vial, LIQUID			
8. Programme duration⁷: 2015 - 2018			
9. Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement) <i>Please note that endorsed or approved amounts for 2019 will be communicated in due course, taking into account updated information on country requirements and following Gavi's review and approval processes.</i>			
	2015-2017	2018	Total⁸
Programme Budget (US\$)	62,868 ⁹	1,493,500	1,556,368
10. Vaccine introduction grant (in US\$): US\$494,000 disbursed on 26 February 2016			
11. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement) ¹⁰			
Type of supplies to be purchased with Gavi funds in each year	2015-2017	2018	
Number of IPV routine program doses		771,400	
Annual Amounts (US\$)	62,868	1,493,500	
12. Procurement agency: UNICEF.			
13. Self-procurement: Not applicable.			
14. Co-financing obligations: Not applicable Gavi's usual co-financing requirements do not apply to IPV. However, Uzbekistan is encouraged to contribute to vaccine and/or supply costs for IPV.			
15. Operational support for campaigns: Not applicable			
16. Additional reporting requirements: Not applicable			
Reports and other information			Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.			15 May
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.			To be agreed with Secretariat
17. Financial clarifications: Not applicable.			

⁶ Please refer to section 18 for additional information on IPV presentation.

⁷ This is the entire duration of the Programme.

⁸ This is the total amount endorsed by Gavi for 2015 to 2018.

⁹ This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

¹⁰ This is the amount that Gavi has approved.

18. Other conditions: Not applicable.

Due to unprecedented demand for IPV and the challenges to scale up production capacities, the global IPV supply remains constrained and is unlikely to meet all country requirements in the short term. As a consequence, the actual presentation and number of doses shipped may differ from those specified in this Decision Letter. In order to mitigate these circumstances, you are strongly encouraged to optimally manage available supply and follow recommendations and guidelines from WHO and UNICEF to reduce vaccine wastage.

If Uzbekistan envisages a switch in product presentation, it is encouraged to incorporate elements for both IPV presentations in your initial introduction preparations, in order to minimise the need for later interventions and facilitate the switch. In those circumstances, in principle, no product switch grant will be provided to Uzbekistan.

Signed by,



On behalf of Gavi

Hind Khatib-Othman
Managing Director, Country Programmes
13 December 2017

**Decision Letter
Uzbekistan - Support for Rotavirus Vaccine**

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Uzbekistan			
2. Grant number: 1718-UZB-13b-X / 13-UZB-08b-Y			
3. Date of Decision Letter: 13/12/2017			
4. Date of the Partnership Framework Agreement: 07/02/2014			
5. Programme title: New Vaccine Support (NVS) - Rotavirus Routine			
6. Vaccine type: Rotavirus			
7. Requested product presentation and formulation of vaccine: Rotavirus, 2 doses schedule			
8. Programme duration¹¹: 2013 -2018			
9. Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement)			
	2014-2017	2018	Total¹²
Programme Budget (US\$)	6,962,065 ¹³	503,500	7,465,565
10. Vaccine introduction grant (in US\$): US\$534,000 disbursed on 04 February 2014.			
11. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement) ¹⁴			
Type of supplies to be purchased with Gavi funds in each year	2014-2017	2018	
Number of Rotavirus vaccines doses		241,500	
Annual Amounts (US\$)	6,962,065 ¹⁵	503,500	
12. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.			
13. Self-procurement: Not applicable.			
14. Co-financing obligations: Reference code: 1718-UZB-13b-X-C According to the co-financing policy, the Country falls within the group Accelerated transition. The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.			
Type of supplies to be purchased with Country funds in each year	2018		
Number of vaccine doses	1,183,500		
Value of vaccine doses (US\$)	2,379,033		
Total co-financing payments (US\$) (including freight)	2,457,000		
15. Operational support for campaigns: Not applicable			
16. Additional reporting requirements: Not applicable			
Reports and other information	Due dates		
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated,	15 May		

¹¹ This is the entire duration of the Programme.

¹² This is the total amount endorsed by Gavi for the entire duration of the Programme.

¹³ This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

¹⁴ This is the amount that Gavi has approved.

¹⁵ This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat
17. Financial clarifications: Not applicable.	
18. Other conditions: Not applicable.	

Signed by,



On behalf of Gavi
Hind Khatib-Othman
Managing Director, Country Programmes
13 December 2017

Decision Letter
Uzbekistan - Support for Injection safety devices

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: The Republic of Uzbekistan				
2. Grant number: 17-UZB-32a-X; 18-UZB-32a-X; 19-UZB-32a-X;				
3. Date of Decision Letter: 13/12/2017				
4. Date of the Partnership Framework Agreement: 07/02/2014				
5. Programme title: Injection Safety Devices ¹⁶				
6. Programme duration¹⁷: 2017 - 2019				
7. Programme Budget (indicative): (subject to the terms of the partnership framework agreement)				
	2017	2018	2019	Total¹⁸
Programme Budget (US\$)	111,875	44,000	25,000	180,875
8. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement) ¹⁹				
TOTAL immunisation supplies to be purchased with Gavi funds in each year	2017	2018		
Number of AD syringes				963,300
Number of re-constitution syringes				
Number of safety boxes				10,600
Annual Amounts for immunisation supplies for all Gavi vaccines (US\$)	111,875	44,000		
Immunisation supplies to be purchased with Gavi funds in each year, by type of support				
New Vaccine Support (NVS), Pneumococcal (PCV13), 1 dose per vial LIQUID, Routine				2018
Number of AD syringes				956,700
Number of re-constitution syringes				
Number of safety boxes				10,550
Annual Amounts for immunisation supplies for Vaccine (US\$)				43,500
New Vaccine Support (NVS), Inactivated Polio Vaccine, 5 doses per vial, LIQUID, Routine				2018
Number of AD syringes				6,600
Number of re-constitution syringes				0
Number of safety boxes				50
Annual Amounts for injection safety devices for Vaccine (US\$)				500
9. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.				

¹⁶ This does not include vaccines.

¹⁷ This is the entire duration of the Programme.

¹⁸ This is the total amount endorsed by Gavi for the entire duration of the Programme.

¹⁹ This is the amount that Gavi has approved.

10. Self-procurement: Not applicable.

11. Co-financing obligations: Co-financing requirements are listed in the relevant vaccine Decision Letter.

Signed by,

Hind A. Khatib

On behalf of Gavi
Hind Khatib-Othman
Managing Director, Country Programmes
13 December 2017